← All drugs
Drug · FAERS side-effect profile with label screen

Albuterol Sulfate side effects: what 291,833 FDA adverse event reports show

Albuterol Sulfate · 1,206 reaction terms · 1,361,834 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Who reports

291,833 reports · 57% serious · 18,583 with death outcome · 65% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Albuterol tablets, USP are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease.

FDA label, Indications and Usage

What it is

Albuterol is a member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom.

PubChem CID 2083 (ChEBI)

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled adverse reaction 1Likely indication confounding 8Reporting / coding artifact 7Lab value / disease marker 4Not in label — unassessed 20
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,166 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Device deposit issue1,814835.9
707.7–987.4ROR 841.1 · calibrated p 3e-16 ✓
64.7 EB05 62.3 · IC025 +5.9
3/3 methods agree
Reporting / coding artifact94% consumerno trial arm names this drug
Wrong technique in product usage process performed in error234265.2
200.1–351.5ROR 265.4 · calibrated p 7e-11 ✓
55.4 EB05 49.7 · IC025 +5.4
3/3 methods agree
Reporting / coding artifact100% consumerno trial arm names this drug
Product cleaning inadequate2,080260.5
237.2–286.1ROR 262.3 · calibrated p 4e-11 ✓
55.4 EB05 53.4 · IC025 +5.7
3/3 methods agree
Reporting / coding artifact100% consumerno trial arm names this drug
Appendicolith262160.3
128.5–199.8ROR 160.4 · calibrated p 4e-9 ✓
48.8 EB05 44.1 · IC025 +5.3
3/3 methods agree
Not in label — unassessedserious n=262 · ♀ 0% (drug 65%) · 100% clinicianno trial arm names this drug
Spirometry abnormal33695.2
80.7–112.2ROR 95.3 · calibrated p 2e-7 ✓
40.5 EB05 37.0 · IC025 +5.1
3/3 methods agree
Lab value / disease markerserious n=332 · ♀ 0% (drug 65%)no trial arm names this drug
Asthma-chronic obstructive pulmonary disease overlap syndrome29693.9
78.8–111.8ROR 94.0 · calibrated p 2e-7 ✓
40.3 EB05 36.6 · IC025 +5.1
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=292 · 100% clinicianno trial arm names this drug
Reversible airways obstruction29293.4
78.4–111.4ROR 93.5 · calibrated p 2e-7 ✓
40.2 EB05 36.5 · IC025 +5.0
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=292no trial arm names this drug
Inhalation therapy36092.2
78.7–107.9ROR 92.3 · calibrated p 2e-7 ✓
40.0 EB05 36.6 · IC025 +5.1
3/3 methods agree
Reporting / coding artifact100% consumerno trial arm names this drug
Mite allergy35589.2
76.2–104.4ROR 89.3 · calibrated p 3e-7 ✓
39.4 EB05 36.1 · IC025 +5.1
3/3 methods agree
Not in label — unassessedserious n=352 · ♀ 0% (drug 65%)no trial arm names this drug
Bronchopulmonary aspergillosis allergic45670.2
61.6–80.0ROR 70.3 · calibrated p 2e-6 ✓
35.3 EB05 32.7 · IC025 +4.9
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=455no trial arm names this drug
Dust allergy46465.7
57.9–74.6ROR 65.8 · calibrated p 2e-6 ✓
34.1 EB05 31.6 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious n=459 · ♀ 0% (drug 65%)no trial arm names this drug
Forced expiratory volume decreased1,31661.3
56.9–66.0ROR 61.6 · calibrated p 4e-6 ✓
32.9 EB05 31.5 · IC025 +4.9
3/3 methods agree
Lab value / disease markerserious n=1,302no trial arm names this drug
Pulmonary vasculitis23154.9
46.2–65.2ROR 54.9 · calibrated p 9e-6 ✓
31.0 EB05 27.8 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=231 · ♀ 0% (drug 65%) · 100% clinicianno trial arm names this drug
Device delivery system issue10,89050.5
49.3–51.8ROR 52.4 · calibrated p 1e-5 ✓
29.6 EB05 29.1 · IC025 +4.9
3/3 methods agree
Reporting / coding artifactserious n=384 · 92% consumerno trial arm names this drug
Bronchial wall thickening29849.3
42.5–57.2ROR 49.3 · calibrated p 2e-5 ✓
29.1 EB05 26.5 · IC025 +4.6
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=298no trial arm names this drug
Mycotic allergy32845.0
39.1–51.7ROR 45.0 · calibrated p 3e-5 ✓
27.6 EB05 25.2 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=322 · ♀ 0% (drug 65%)no trial arm names this drug
Ejection fraction20839.0
32.9–46.2ROR 39.0 · calibrated p 7e-5 ✓
25.2 EB05 22.5 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=208 · ♀ 100% (drug 65%)no trial arm names this drug
Obstructive airways disorder3,89637.8
36.4–39.3ROR 38.3 · calibrated p 7e-5 ✓
24.8 EB05 24.2 · IC025 +4.6
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
age-adj. PRR 41.2 · serious PRR 26.0no trial arm names this drug
Sensitisation26637.5
32.3–43.6ROR 37.6 · calibrated p 8e-5 ✓
24.6 EB05 22.2 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=265 · ♀ 100% (drug 65%)no trial arm names this drug
Bronchial secretion retention42435.6
31.6–40.0ROR 35.6 · calibrated p 1e-4 ✓
23.8 EB05 22.0 · IC025 +4.4
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=408no trial arm names this drug
Forced vital capacity decreased21234.2
29.0–40.4ROR 34.3 · calibrated p 1e-4 ✓
23.2 EB05 20.7 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=211 · 100% clinicianno trial arm names this drug
Full blood count abnormal3,42633.9
32.6–35.3ROR 34.3 · calibrated p 1e-4 ✓
23.1 EB05 22.4 · IC025 +4.5
3/3 methods agree
Lab value / disease markerserious PRR 31.0no trial arm names this drug
Pulmonary function test abnormal49933.1
29.7–36.8ROR 33.1 · calibrated p 2e-4 ✓
22.7 EB05 21.1 · IC025 +4.3
3/3 methods agree
Reporting / coding artifactserious n=482no trial arm names this drug
Blood immunoglobulin e increased73130.2
27.7–32.9ROR 30.3 · calibrated p 3e-4 ✓
21.3 EB05 20.0 · IC025 +4.3
3/3 methods agree
Lab value / disease markerserious n=703no trial arm names this drug
Increased bronchial secretion76930.1
27.7–32.8ROR 30.2 · calibrated p 3e-4 ✓
21.3 EB05 20.0 · IC025 +4.3
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=736 · 83% consumerno trial arm names this drug
Sleep disorder due to a general medical condition4,58027.8
26.9–28.8ROR 28.2 · calibrated p 4e-4 ✓
20.1 EB05 19.6 · IC025 +4.3
3/3 methods agree
Not in label — unassessedage-adj. PRR 25.5 · serious PRR 36.0no trial arm names this drug
Allergy to animal27725.2
22.0–28.9ROR 25.2 · calibrated p 7e-4 ✓
18.7 EB05 16.9 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=261no trial arm names this drug
Conjunctivitis allergic38425.0
22.3–28.1ROR 25.1 · calibrated p 7e-4 ✓
18.6 EB05 17.1 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=374 · ♀ 0% (drug 65%)no trial arm names this drug
Lung hyperinflation22124.2
20.7–28.2ROR 24.2 · calibrated p 8e-4 ✓
18.1 EB05 16.2 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=217 · ♀ 0% (drug 65%)no trial arm names this drug
Device ineffective26523.1
20.1–26.6ROR 23.1 · calibrated p 0.001 ✓
17.6 EB05 15.9 · IC025 +3.9
3/3 methods agree
Reporting / coding artifact♀ 0% (drug 65%) · 100% consumerno trial arm names this drug
Eosinophilic granulomatosis with polyangiitis49022.5
20.4–25.0ROR 22.6 · calibrated p 0.001 ✓
17.2 EB05 16.0 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=490 · ♀ 0% (drug 65%)no trial arm names this drug
Total lung capacity decreased38722.4
20.0–25.1ROR 22.4 · calibrated p 0.001 ✓
17.2 EB05 15.8 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=356no trial arm names this drug
Obstructive sleep apnoea syndrome33021.8
19.2–24.6ROR 21.8 · calibrated p 0.001 ✓
16.8 EB05 15.3 · IC025 +3.9
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=320no trial arm names this drug
Circumstance or information capable of leading to device use error55621.8
19.8–23.9ROR 21.8 · calibrated p 0.001 ✓
16.8 EB05 15.6 · IC025 +3.9
3/3 methods agree
Not in label — unassessed100% consumerno trial arm names this drug
Sputum discoloured2,21221.5
20.5–22.5ROR 21.6 · calibrated p 0.001 ✓
16.6 EB05 16.1 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious PRR 20.8no trial arm names this drug
Wheezing13,73121.3
20.9–21.7ROR 22.2 · calibrated p 0.001 ✓
16.5 EB05 16.3 · IC025 +4.0
3/3 methods agree
Not in label — unassessedage-adj. PRR 21.3 · serious PRR 18.6no trial arm names this drug
Rhinitis allergic1,02321.0
19.6–22.6ROR 21.1 · calibrated p 0.002 ✓
16.4 EB05 15.5 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=962no trial arm names this drug
Respiratory symptom64220.9
19.1–22.8ROR 20.9 · calibrated p 0.002 ✓
16.3 EB05 15.2 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=611 · ♀ 34% (drug 65%)no trial arm names this drug
Nasal polyps1,09720.7
19.3–22.1ROR 20.8 · calibrated p 0.002 ✓
16.1 EB05 15.4 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=1,014no trial arm names this drug
Asthma24,78120.0
19.7–20.2ROR 21.7 · calibrated p 0.001 ✓
15.7 EB05 15.5 · IC025 +4.0
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 22.4 · serious PRR 18.3no trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Serious infection25,3922.42.4–2.4signal
Interstitial lung disease2,5151.91.8–2.0raised
Depression7,0061.81.8–1.9raised
Anaphylaxis / angioedema3,0441.81.7–1.8raised
Arrhythmia / qt4,3731.61.6–1.7raised
Venous thromboembolism4,8581.61.6–1.7raised
Fall / fracture8,4321.61.6–1.6raised
Heart failure3,9441.61.5–1.6raised
Hyponatraemia1,7731.61.5–1.7raised
Tendon disorder7801.51.4–1.6raised
Gi bleeding3,4141.31.3–1.4raised
Kidney injury8,2521.31.3–1.3raised
Anaemia5,1401.21.2–1.3raised
Opportunistic infection2,2851.21.2–1.3raised
Hyperglycaemia / diabetes5,6911.21.2–1.2raised
Myocardial infarction3,2401.11.1–1.2raised

Trial evidence (ClinicalTrials.gov)

No completed trial with posted adverse-event results was found on ClinicalTrials.gov for Albuterol (searched ALBUTEROL).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Dyspnoea (shortness of breath)42,6405.7
5.7–5.8ROR 6.5 · calibrated p 0.120
5.4 EB05 5.3 · IC025 +2.4
3/3 methods agree
Not in label — unassessedage-adj. PRR 5.2 · serious PRR 5.0no trial arm names this drug
Asthma24,78120.0
19.7–20.2ROR 21.7 · calibrated p 0.001 ✓
15.7 EB05 15.5 · IC025 +4.0
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 22.4 · serious PRR 18.3no trial arm names this drug
Drug ineffective (drug did not work)22,8301.2
1.2–1.3ROR 1.3 · calibrated p 0.478
1.2 EB05 1.2 · IC025 +0.3Reporting / coding artifactage-adj. PRR 1.5 · serious PRR 1.7no trial arm names this drug
Cough20,2975.5
5.4–5.6ROR 5.8 · calibrated p 0.162
5.2 EB05 5.1 · IC025 +2.3
3/3 methods agree
Not in label — unassessedage-adj. PRR 5.6 · serious PRR 6.4no trial arm names this drug
Wrong technique in product usage process18,7907.2
7.1–7.3ROR 7.6 · calibrated p 0.077
6.6 EB05 6.5 · IC025 +2.7
3/3 methods agree
Reporting / coding artifactage-adj. PRR 2.4 · serious PRR 2.7 · 95% consumerno trial arm names this drug
Fatigue (tiredness)16,7191.5
1.5–1.6ROR 1.6 · calibrated p 0.689
1.5 EB05 1.5 · IC025 +0.6Not in label — unassessedage-adj. PRR 1.7 · serious PRR 2.1no trial arm names this drug
Pneumonia (lung infection)16,6753.8
3.8–3.9ROR 4.0 · calibrated p 0.381
3.7 EB05 3.6 · IC025 +1.8
3/3 methods agree
Not in label — unassessedage-adj. PRR 3.8 · serious PRR 3.8no trial arm names this drug
Headache15,6061.8
1.8–1.8ROR 1.8 · calibrated p 0.851
1.8 EB05 1.7 · IC025 +0.8Labeled adverse reaction
exact term
age-adj. PRR 1.9 · serious PRR 2.6no trial arm names this drug
Nausea14,6121.3
1.3–1.3ROR 1.3 · calibrated p 0.534
1.3 EB05 1.3 · IC025 +0.4Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 1.8no trial arm names this drug
Wheezing13,73121.3
20.9–21.7ROR 22.2 · calibrated p 0.001 ✓
16.5 EB05 16.3 · IC025 +4.0
3/3 methods agree
Not in label — unassessedage-adj. PRR 21.3 · serious PRR 18.6no trial arm names this drug
Off label use (used outside approved label)13,4541.1
1.1–1.1ROR 1.1 · calibrated p 0.378
1.1 EB05 1.1 · IC025 +0.1Reporting / coding artifactage-adj. PRR 1.1 · serious PRR 1.3no trial arm names this drug
Pain12,9081.5
1.5–1.5ROR 1.5 · calibrated p 0.657
1.5 EB05 1.5 · IC025 +0.5Not in label — unassessedage-adj. PRR 2.0 · serious PRR 1.9no trial arm names this drug
Diarrhoea (diarrhea)12,0361.3
1.3–1.4ROR 1.4 · calibrated p 0.542
1.3 EB05 1.3 · IC025 +0.4Not in label — unassessedage-adj. PRR 1.4 · serious PRR 1.7no trial arm names this drug
Malaise (feeling unwell)11,2291.8
1.8–1.9ROR 1.9 · calibrated p 0.871
1.8 EB05 1.8 · IC025 +0.8Not in label — unassessedage-adj. PRR 2.0 · serious PRR 2.3no trial arm names this drug
Device delivery system issue10,89050.5
49.3–51.8ROR 52.4 · calibrated p 1e-5 ✓
29.6 EB05 29.1 · IC025 +4.9
3/3 methods agree
Reporting / coding artifactserious n=384 · 92% consumerno trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Gentamicin Sulfate ↔ Renal Failure.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Albuterol?

In FDA FAERS, the most frequently co-reported reaction terms for Albuterol are dyspnoea, asthma, cough, fatigue, pneumonia, headache. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Albuterol have an FDA boxed warning?

No. The FDA label retrieved for Albuterol has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Albuterol causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.